Drug Profile
Neurological disorders stem cell therapies - TCA Cellular Therapy
Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator TCA Cellular Therapy
- Class Mesenchymal stem cell therapies; Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Amyotrophic lateral sclerosis; Spinal cord injuries
Most Recent Events
- 29 Jun 2015 Discontinued - Phase-I for Amyotrophic lateral sclerosis in USA (Intrathecal)
- 29 Jun 2015 Discontinued - Phase-I for Spinal cord injuries in USA (Intrathecal)
- 01 May 2014 Suspended - Phase-I for Amyotrophic lateral sclerosis in USA (Intrathecal)